MA33751B1 - Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 - Google Patents

Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Info

Publication number
MA33751B1
MA33751B1 MA34869A MA34869A MA33751B1 MA 33751 B1 MA33751 B1 MA 33751B1 MA 34869 A MA34869 A MA 34869A MA 34869 A MA34869 A MA 34869A MA 33751 B1 MA33751 B1 MA 33751B1
Authority
MA
Morocco
Prior art keywords
orl
compounds
treatment
spirobridine
receptor antagonists
Prior art date
Application number
MA34869A
Other languages
Arabic (ar)
English (en)
Inventor
Collado Ana Belen Benito
Buezo Nuria Diaz
Alma Maria Jimenez-Aguado
Blanco Celia Lafuente
Maria Angeles Martinez-Grau
Concepcion Pedregal-Tercero
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33751B1 publication Critical patent/MA33751B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un antagoniste de récepteur orl-1 de formule i, ses utilisations et procédés de préparation. Des antagonistes de orl-1 sont jugés utiles dans le traitement de la dépression et/ou le traitement du surpoids, de l'obésité, et/ou le maintien du poids après un traitement du surpoids ou de l'obésité. Certains composés ont également montré dans des modèles animaux que les composés de la présente invention sont utiles pour le traitement de migraines.
MA34869A 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1 MA33751B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27
PCT/US2010/056180 WO2011060035A1 (fr) 2009-11-16 2010-11-10 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Publications (1)

Publication Number Publication Date
MA33751B1 true MA33751B1 (fr) 2012-11-01

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34869A MA33751B1 (fr) 2009-11-16 2012-05-14 Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1

Country Status (34)

Country Link
US (1) US8232289B2 (fr)
EP (1) EP2501703B1 (fr)
JP (1) JP5680101B2 (fr)
KR (1) KR101363830B1 (fr)
CN (1) CN102612520B (fr)
AR (1) AR078863A1 (fr)
AU (1) AU2010319581C1 (fr)
CA (1) CA2796161C (fr)
CO (1) CO6541545A2 (fr)
CR (1) CR20130087A (fr)
DK (1) DK2501703T3 (fr)
DO (1) DOP2012000135A (fr)
EA (1) EA020848B1 (fr)
EC (1) ECSP12011902A (fr)
ES (1) ES2435814T3 (fr)
HN (1) HN2012001011A (fr)
HR (1) HRP20130967T1 (fr)
IL (1) IL219370A (fr)
JO (1) JO2887B1 (fr)
MA (1) MA33751B1 (fr)
ME (1) ME01537B (fr)
MX (1) MX2012005691A (fr)
MY (1) MY160665A (fr)
NZ (1) NZ600006A (fr)
PE (1) PE20121430A1 (fr)
PH (1) PH12012500969A1 (fr)
PL (1) PL2501703T3 (fr)
PT (1) PT2501703E (fr)
RS (1) RS53018B (fr)
SI (1) SI2501703T1 (fr)
TW (1) TWI465453B (fr)
UA (1) UA107943C2 (fr)
WO (1) WO2011060035A1 (fr)
ZA (1) ZA201202967B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201510665WA (en) 2009-12-04 2016-01-28 Sunovion Pharmaceuticals Inc Multicycle Compounds And Pharmaceutical Compositions Useful For The Treatment Of Neurological Disorders
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
DK2903440T3 (en) 2012-10-02 2017-12-11 Bayer Cropscience Ag THETEROCYCLIC COMPOUNDS AS PESTICIDES
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MX390141B (es) 2017-02-16 2025-03-20 Sunovion Pharmaceuticals Inc Metodos para tratar esquizofrenia
HUE054483T2 (hu) 2017-03-02 2021-09-28 Lilly Co Eli ROR-gamma-T gátlására alkalmas vegyületek
US10603320B2 (en) * 2017-03-02 2020-03-31 Eli Lilly And Company Compounds useful for inhibiting ROR-gamma-t
CA3070993C (fr) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. Composés d’isochromane et leurs utilisations
UA130249C2 (uk) 2018-02-16 2025-12-31 Сумітомо Фарма Америка, Інк. Солі, кристалічні форми і способи їх отримання
US11618746B2 (en) 2018-12-17 2023-04-04 Vertex Pharmaceuticals Incorporated Inhibitors of APOL1 and methods of using same
EP3938045A1 (fr) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Sels d'un composé d'isochromanyle et formes cristallines, procédés de préparation, utilisations thérapeutiques et compositions pharmaceutiques associées
CA3180115A1 (fr) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7 h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine pour le traitement de troubles neurologiques et psychiatriques
CN115867543A (zh) 2020-06-12 2023-03-28 弗特克斯药品有限公司 Apol1抑制剂的固体形式及其使用方法
CN116547287B (zh) 2020-08-26 2025-09-26 弗特克斯药品有限公司 Apol1的抑制剂及其使用方法
CA3251050A1 (fr) * 2022-02-08 2023-08-17 Vertex Pharmaceuticals Incorporated Dérivés de 2-méthyl-4',5'-dihydrospiro[pipéridine-4,7'-thiéno[2,3-c]pyran] utilisés en tant qu'inhibiteurs de apol1 et leurs procédés d'utilisation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US6686370B2 (en) * 1999-12-06 2004-02-03 Euro-Celtique S.A. Triazospiro compounds having nociceptin receptor affinity
KR100628292B1 (ko) * 2001-04-18 2006-09-27 유로-셀티크 소시에떼 아노뉨 스파이로파이라졸 화합물
WO2002088089A1 (fr) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Derives de spiropiperidine, antagonistes du recepteur de nociceptine les contenant en tant qu'ingredient actif et compositions medicinales
ATE396995T1 (de) * 2001-07-23 2008-06-15 Banyu Pharma Co Ltd 4-oxoimidazolidin-2-spiro piperidin derivat
BR0307268A (pt) * 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
WO2003095427A1 (fr) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Compose a noyau spiranique
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
JP4712384B2 (ja) * 2002-09-09 2011-06-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｏｒｌ−１受容体介在障害の治療に有用なヒドロキシアルキル置換１，３，８−トリアザスピロ［４．５］デカン−４−オン誘導体
WO2005016913A1 (fr) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
US7354925B2 (en) * 2004-03-29 2008-04-08 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as ORL1-receptor antagonists
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (fr) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. Derivés spiro[piperidine-4,4'-thieno[3,2-c]pyran] et composés similaires en tant que inhibiteurs du recepteur sigma pour le traitement de pyschose
PT2260042E (pt) * 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos

Also Published As

Publication number Publication date
SI2501703T1 (sl) 2013-11-29
DK2501703T3 (da) 2013-10-14
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
CN102612520B (zh) 2015-04-08
CR20130087A (es) 2013-04-17
PL2501703T3 (pl) 2014-02-28
EA201290352A1 (ru) 2012-10-30
DOP2012000135A (es) 2012-08-15
RS53018B (sr) 2014-04-30
AU2010319581A1 (en) 2012-06-07
TW201127841A (en) 2011-08-16
MX2012005691A (es) 2012-06-13
US8232289B2 (en) 2012-07-31
ES2435814T3 (es) 2013-12-23
JO2887B1 (en) 2015-03-15
PH12012500969A1 (en) 2013-01-07
EA020848B1 (ru) 2015-02-27
ME01537B (me) 2014-04-20
PE20121430A1 (es) 2012-10-26
US20110118251A1 (en) 2011-05-19
JP2013510859A (ja) 2013-03-28
AU2010319581B2 (en) 2013-12-19
JP5680101B2 (ja) 2015-03-04
HK1169988A1 (en) 2013-02-15
IL219370A0 (en) 2012-06-28
ECSP12011902A (es) 2012-07-31
EP2501703B1 (fr) 2013-09-18
CN102612520A (zh) 2012-07-25
HRP20130967T1 (hr) 2013-11-22
CA2796161C (fr) 2015-03-17
PT2501703E (pt) 2013-11-26
WO2011060035A1 (fr) 2011-05-19
HN2012001011A (es) 2015-08-31
AU2010319581C1 (en) 2014-05-15
EP2501703A1 (fr) 2012-09-26
MY160665A (en) 2017-03-15
UA107943C2 (xx) 2015-03-10
CA2796161A1 (fr) 2011-05-19
AR078863A1 (es) 2011-12-07
KR20130026523A (ko) 2013-03-13
KR101363830B1 (ko) 2014-02-14
CO6541545A2 (es) 2012-10-16
IL219370A (en) 2015-01-29
NZ600006A (en) 2014-05-30

Similar Documents

Publication Publication Date Title
MA33751B1 (fr) Composés de spiropipéridine en tant qu'antagonistes de récepteur orl-1
PT2501704E (pt) Compostos de espiropiperidina como antagonistas do receptor orl-1
DE602008005771D1 (de) Disubstituierte alkyl-8-azabicycloä3.2.1üoktan-verbindungen als mu-opioid-rezeptorantagonisten
MA34650B1 (fr) Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
MA31158B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
WO2008112159A3 (fr) Antagonistes des récepteurs cgrp d'anilide spirolactame monocyclique
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
EP1797073A4 (fr) Antagonistes des recepteurs du cgrp de spirolactame anilide bicyclique
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
DE602005020472D1 (de) Tricyclische anilid-spirohydantoin-cgrp-rezeptorantagonisten
JO3346B1 (ar) مواد مضادة C5aR
EP1796678A4 (fr) Carboxamide spirolactam cgrp receptor antagonists
TW200505903A (en) CGRP receptor antagonists
WO2004082605A3 (fr) Antagonistes des recepteurs du cgrp spirohydantoine anilides bicycliques
MA33155B1 (fr) Composes organiques et leurs utilisations
MA31766B1 (fr) Composés organiques
ATE517106T1 (de) Kondensierte spiropiperidine als modulatoren muskarinartiger rezeptoren
ATE537153T1 (de) Arylspirolactamverbindungen als antagonisten des cgrp-rezeptors
CH707539A8 (fr) Alliage d'or rose pour pièce d'horlogerie.
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
ATE518852T1 (de) Tricyclische anilid-spirohydantoin-cgrp- rezeptorantagonisten
GB2498268A (en) Silicone protectant compositions
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors